clinical trial · NCT03647878
Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.
Advanced Renal Cell CarcinomaMetastatic Renal Cell Carcinoma
brief summary
The purpose of the protocol, is to describe the use of cabozantinib tablets as monotherapy or in combination with nivolumab including the number of dose reductions, dose interruptions and terminations due to (serious) adverse events in subjects with advanced or metastatic renal cell carcinoma (mRCC) treated in real-life clinical setting in 1st line treatment.
started
Sep 24, 2018
primary completion
Sep 30, 2027
completion
Sep 30, 2027
last updated
Jun 30, 2026
official title
Prospective Non-interventional Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol